These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 19580675)
1. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Kamal SA Virol J; 2009 Jul; 6():94. PubMed ID: 19580675 [TBL] [Abstract][Full Text] [Related]
2. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. Botros B; Omar A; Elian K; Mohamed G; Soliman A; Salib A; Salman D; Saad M; Earhart K J Med Virol; 2006 Jun; 78(6):787-91. PubMed ID: 16628582 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12ΔNSm21/384 vaccine candidate for sheep, goats and calves. Boumart Z; Daouam S; Bamouh Z; Jazouli M; Tadlaoui KO; Dungu B; Bettinger G; Watts DM; Elharrak M Vaccine; 2019 Mar; 37(12):1642-1650. PubMed ID: 30773401 [TBL] [Abstract][Full Text] [Related]
4. Novel approaches to develop Rift Valley fever vaccines. Indran SV; Ikegami T Front Cell Infect Microbiol; 2012; 2():131. PubMed ID: 23112960 [TBL] [Abstract][Full Text] [Related]
5. Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments. Ikegami T; Hill TE; Smith JK; Zhang L; Juelich TL; Gong B; Slack OA; Ly HJ; Lokugamage N; Freiberg AN J Virol; 2015 Jul; 89(14):7262-76. PubMed ID: 25948740 [TBL] [Abstract][Full Text] [Related]
6. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Ikegami T Expert Rev Vaccines; 2017 Jun; 16(6):601-611. PubMed ID: 28425834 [TBL] [Abstract][Full Text] [Related]
7. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Morrill JC; Mebus CA; Peters CJ Am J Vet Res; 1997 Oct; 58(10):1110-4. PubMed ID: 9328663 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12ΔNSm21/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania. Nyundo S; Adamson E; Rowland J; Palermo PM; Matiko M; Bettinger GE; Wambura P; Morrill JC; Watts DM Onderstepoort J Vet Res; 2019 Jan; 86(1):e1-e8. PubMed ID: 30843406 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. von Teichman B; Engelbrecht A; Zulu G; Dungu B; Pardini A; Bouloy M Vaccine; 2011 Aug; 29(34):5771-7. PubMed ID: 21664400 [TBL] [Abstract][Full Text] [Related]
10. Modifying the NSs gene to improve live-attenuated vaccine for Rift Valley fever. Lihoradova O; Ikegami T Expert Rev Vaccines; 2012 Nov; 11(11):1283-5. PubMed ID: 23249225 [No Abstract] [Full Text] [Related]
11. Distinct Pathological Changes in Preweaning Mice Infected with Live-Attenuated Rift Valley Fever Virus Strains. Alkan C; Jurado-Cobena E; Ikegami T Viruses; 2024 Jun; 16(7):. PubMed ID: 39066162 [TBL] [Abstract][Full Text] [Related]
12. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice. Indran SV; Lihoradova OA; Phoenix I; Lokugamage N; Kalveram B; Head JA; Tigabu B; Smith JK; Zhang L; Juelich TL; Gong B; Freiberg AN; Ikegami T J Gen Virol; 2013 Jul; 94(Pt 7):1441-1450. PubMed ID: 23515022 [TBL] [Abstract][Full Text] [Related]
13. Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates. Pittman PR; Norris SL; Brown ES; Ranadive MV; Schibly BA; Bettinger GE; Lokugamage N; Korman L; Morrill JC; Peters CJ Vaccine; 2016 Jan; 34(4):523-530. PubMed ID: 26706271 [TBL] [Abstract][Full Text] [Related]
14. Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. Makoschey B; van Kilsdonk E; Hubers WR; Vrijenhoek MP; Smit M; Wichgers Schreur PJ; Kortekaas J; Moulin V PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004550. PubMed ID: 27031621 [TBL] [Abstract][Full Text] [Related]
15. MBT/Pas mouse: a relevant model for the evaluation of Rift Valley fever vaccines. Ayari-Fakhfakh E; do Valle TZ; Guillemot L; Panthier JJ; Bouloy M; Ghram A; Albina E; Cêtre-Sossah C J Gen Virol; 2012 Jul; 93(Pt 7):1456-1464. PubMed ID: 22513390 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of Onderstepoort Biological Products' Rift Valley fever Clone 13 vaccine in sheep and goats under field conditions in Senegal. Lo MM; Mbao V; Sierra P; Thiongane Y; Diop M; Donadeu M; Dungu B Onderstepoort J Vet Res; 2015 May; 82(1):857. PubMed ID: 26244679 [TBL] [Abstract][Full Text] [Related]
17. Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain. Ly HJ; Nishiyama S; Lokugamage N; Smith JK; Zhang L; Perez D; Juelich TL; Freiberg AN; Ikegami T Vaccine; 2017 Dec; 35(48 Pt B):6634-6642. PubMed ID: 29061350 [TBL] [Abstract][Full Text] [Related]
18. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Hunter P; Erasmus BJ; Vorster JH Onderstepoort J Vet Res; 2002 Mar; 69(1):95-8. PubMed ID: 12092782 [TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels. Daouam S; Ghzal F; Naouli Y; Tadlaoui KO; Ennaji MM; Oura C; El Harrak M BMC Vet Res; 2016 Jul; 12(1):154. PubMed ID: 27457539 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Morrill JC; Laughlin RC; Lokugamage N; Pugh R; Sbrana E; Weise WJ; Adams LG; Makino S; Peters CJ Vaccine; 2013 Jan; 31(3):559-65. PubMed ID: 23153443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]